Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$3.14
$0.00(0.00%)
At close: 4:00 PM EDT
$3.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.07 - $71.50
Previous CloseN/A
Volume9.08K
Average Volume (3M)100.88K
Market Cap
$2.20M
Enterprise Value$11.20
Total Cash (Recent Filing)$1.54M
Total Debt (Recent Filing)$5.86M
Price to Earnings (P/E)―
Beta24.53
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.45
Shares Outstanding1,666,100
10 Day Avg. Volume190,227
30 Day Avg. Volume100,883
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CAB Oncology PlatformBioAtla’s CAB platform is designed to concentrate therapeutic activity in the tumor microenvironment, potentially improving tolerability and efficacy. If clinical validation continues, this differentiated approach could support multiple oncology candidates and create durable strategic value beyond a single program.
Revenue ReboundThe sharp TTM revenue rebound indicates that BioAtla has generated materially more collaboration, partnership, or research-linked revenue than in the prior period. Although revenue remains modest and volatile, this increase could strengthen funding capacity if it proves repeatable across future development cycles.
Improved Cash-burn TrendOperating cash burn has improved substantially from the prior year, suggesting expense control and/or better working-capital dynamics. Continued progress would extend the company’s operational runway and reduce the pace at which external capital is required, even though cash generation remains negative.
Bears Say
Negative Stockholders’ EquityNegative equity signals a severely weakened capital base and limits financial flexibility. Declining assets alongside continued losses may make it harder to support clinical development internally, while the negative capital position increases dependence on financing and the potential for shareholder dilution.
Persistent UnprofitabilityBioAtla remains far from breakeven despite the revenue rebound, with substantial net losses and negative operating and EBITDA margins. This indicates that current activities do not yet cover the cost of development, leaving future financial performance dependent on pipeline progress or additional funding.
Nasdaq Delisting And OTC MoveThe affirmed delisting represents a structural change in the company’s trading venue that can reduce market access, liquidity, and visibility for investors. The transition may also complicate future capital raising and make it harder for the company to attract or retain institutional support.
BioAtla News
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $1.07 and its highest was $71.50 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $2.20M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Nov 18, 2026 which is in 73 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Aug 06, 2026. The company reported $0.272 earnings per share for the quarter.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Overvalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioAtla have?
BioAtla has 1,666,100 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of $0.272 in its last earnings report. Following the earnings report the stock price went up 0.15%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioAtla
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
26.98% Insiders
11.77% Mutual Funds
1.02% Other Institutional Investors
59.23% Public Companies and
Individual Investors